• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Mirada recruits German hospital

Article

University Hospital Essen has signed an agreement with Mirada Solutions, a unit of CTI Molecular Imaging, to serve as the company's first European clinical reference site. German physicians will use Mirada software in a combined PET/CT environment to

University Hospital Essen has signed an agreement with Mirada Solutions, a unit of CTI Molecular Imaging, to serve as the company's first European clinical reference site. German physicians will use Mirada software in a combined PET/CT environment to address software fusion requirements as a complement to conventional hardware-based techniques. The hospital has been working with PET/CT imaging since October 2001. The collaboration is the first step toward establishing R&D partnerships among leading European institutions, CTI, and its subsidiaries, including Mirada Solutions and PETNET Pharmaceuticals. Mirada joined CTI Aug. 18, when CTI purchased all of Mirada's capital stock.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.